GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Casp3 | increases activity | EXP | | 6480464 | CTD | Galactosamine results in increased activity of CASP3 protein | PMID:15610455 | Casp3 | increases expression | EXP | | 6480464 | CTD | Galactosamine results in increased expression of CASP3 mRNA; Galactosamine results in increased expression of CASP3 protein | PMID:22118634 PMID:22310181 PMID:24565947 | Casp3 | multiple interactions | EXP | | 6480464 | CTD | 2-Acetylaminofluorene inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased cleavage of CASP3 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased cleavage of CASP3 protein; Alprostadil inhibits the reaction [Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein]; Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of CASP3 mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of CASP3 protein] | PMID:12907702 PMID:15565661 PMID:21401295 PMID:22118634 PMID:22310181 PMID:24565947 | Casp3 | multiple interactions | ISO | Casp3 (Mus musculus) | 6480464 | CTD | 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP3 protein]; [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein; [Galactosamine co-treated with Endotoxins] results in increased activity of CASP3 protein; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein modified form; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP3 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; [Nitric Oxide Donors results in increased abundance of Nitric Oxide] inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]; [TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form]; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein]; Biliverdine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]]; Dithiothreitol inhibits the reaction [Nitric Oxide Donors inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]]; gentiopicroside inhibits the reaction [[[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein modified form]; Melatonin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein]; Methylene Chloride inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP3 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form]; TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein] | PMID:14512878 PMID:15486963 PMID:17602819 PMID:20558151 PMID:20850421 PMID:21146893 PMID:22023962 PMID:24830863 PMID:28887131 PMID:31332890 PMID:32453893 PMID:9388267 | Casp3 | multiple interactions | ISO | CASP3 (Homo sapiens) | 6480464 | CTD | [Galactosamine co-treated with TNF protein] results in increased activity of CASP3 protein; alpha-Tocopherol inhibits the reaction [Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein]; Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein; Ketoconazole inhibits the reaction [Galactosamine results in increased activity of CASP3 protein]; Rifampin promotes the reaction [Galactosamine results in increased activity of CASP3 protein] | PMID:17936189 PMID:26176423 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |